The upper face is where most injectors start — and where many stay for longer than they need to. There is nothing wrong with that. Frontalis, glabella, and crow's feet are high-volume, high-repeat services that form the economic core of most aesthetic practices. But at some point, your patients start asking for things you can't offer yet: a slimmer jawline, a Nefertiti lift, a lip flip, or relief from the hyperhidrosis that no antiperspirant has touched. That is when the question of advanced training becomes real.
This guide is written from the perspective of someone who performs these techniques every week and teaches them to licensed providers in Phoenix. The lower face is not simply more of the same thing — it is a different clinical environment that requires different preparation. Here is what you actually need to know before you pursue advanced training, and what to look for when evaluating a course.
Why the Lower Face Is Clinically Different
The upper face is mechanically predictable. The frontalis, corrugators, and orbicularis oculi sit in well-defined anatomical positions with relatively consistent depth and low adjacency risk. With training in the core three zones and enough patient volume to build pattern recognition, a competent injector can deliver reliable results with a manageable complication profile.
The lower face does not work this way. The muscles are smaller, more numerous, and more densely interconnected. Injection points are closer to structures — the marginal mandibular nerve, the depressor labii, the orbicularis oris — where an off-target placement does not produce a slightly uneven brow. It produces a mouth that cannot form a smile correctly, or a lip that cannot close fully, or an asymmetry that takes three to four months to resolve and cannot be hyaluronidase'd away.
Ptosis from a misplaced frontalis injection is cosmetically displeasing and takes weeks to resolve. Weakness of the depressor labii from an imprecise DAO correction can affect speech, eating, and expression for the duration of the toxin's effect. The difference between upper and lower face injecting is not just anatomical — it is the nature of the consequence when something goes wrong.
This distinction is not meant to discourage providers from advancing. It is meant to establish why lower face technique requires dedicated training, not extrapolation from upper face experience.
The Six Advanced Techniques Worth Learning
Not every lower face application gets equal clinical use. The following six are the ones most commonly added to a medspa menu and most commonly requested by patients — ranked roughly by frequency of use in a busy aesthetic practice.
Botulinum toxin injected into the masseter muscle to reduce jaw bulk and soften a square jawline — or to relieve bruxism-related clenching and grinding. This is the most commonly requested advanced neurotoxin treatment in medspa-adjacent aesthetic practice. Volumes are substantial (typically 25–50 units per side), results are dramatic and appreciated, and repeat patients are reliable. The anatomical landmarks are learnable, but depth and placement precision matter significantly — superficial injection produces a visible bulge with no functional reduction. A clear understanding of masseter anatomy and palpation technique before injecting is essential.
Treatment of the DAO muscle to address downturned mouth corners — the appearance often described by patients as "always looking unhappy." This is one of the most impactful and least-taught lower face techniques. When done correctly, it produces a meaningful improvement in resting expression without touching lip architecture. When done incorrectly — placement too superior, too close to the depressor labii inferioris, or at the wrong depth — it produces a visible asymmetry that affects oral function. Anatomical precision here is not optional. This technique requires a clear understanding of the muscle's origin and insertion relative to adjacent structures before any patient is treated.
Low-dose orbicularis oris relaxation to produce the appearance of a fuller upper lip without volume — commonly performed as a standalone treatment or as a complement to lip filler. The lip flip is technically accessible and uses small doses (typically 4–8 units), but it requires patient selection judgment that comes with experience: certain patients cannot tolerate the functional compromise to the orbicularis (particularly those who play wind instruments, have a high patient-facing role, or have existing lip weakness) and others will have expectations of volumization that a lip flip cannot meet. Informed consent and treatment expectation management are as important as injection technique here.
Serial injections along the lower jawline and into the anterior platysmal bands to relax the downward pull of the platysma, produce a subtle jawline lift, and soften neck banding. This technique requires a working understanding of platysmal anatomy and the ability to accurately identify and palpate the bands before injecting. Dose volumes are moderate to high (30–60 units across the treatment area is common), and injection depth varies between the jawline and neck portions of the treatment. Patients who benefit most from the Nefertiti lift tend to be in their late 30s to early 50s with early-to-moderate platysmal banding — patient selection is a core competency for this treatment.
Treatment of the mentalis muscle to soften the "pebbly" or "orange peel" texture that appears on the chin at rest or with movement. A smaller, more targeted treatment than masseter or Nefertiti, but one where over-treatment produces a visible functional deficit — patients who receive too much mentalis treatment can develop temporary difficulty expressing emotion through the lower face. Conservative dosing (typically 5–10 units total) and careful patient selection separate good outcomes from corrections that require follow-up visits.
Botulinum toxin injected intradermally into the axillary skin to block eccrine sweat gland activation and reduce excessive sweating. This is the most straightforwardly rewarding treatment to add: results are dramatic (typically 82–87% reduction in sweating based on published data), patients are grateful in a way that aesthetic patients rarely match, repeat visits at 6–9 month intervals are predictable, and the technique itself — a grid injection pattern into superficial dermis — is learnable. It is also one of the few botulinum toxin applications with an FDA-approved therapeutic indication, which simplifies the consent and documentation process. The primary learning curve is the starch-iodine test for marking the treatment zone and the intradermal injection depth, which is shallower than most providers initially assume.
How to Know When You Are Ready
There is no certification board that declares a provider ready for advanced neurotoxin technique. The decision is yours, and it should be made honestly. The following framework is based on how I evaluate readiness when providers inquire about advanced training — not as a gate to keep people out, but as a diagnostic to prevent them from advancing before the foundation is solid enough to support it.
The most important item on the "not ready" list is the last one. A provider who begins offering advanced lower face neurotoxins without updated standing orders from their medical director is operating outside their documented scope — regardless of how competent they are technically. When a practice expands its service menu, the documentation must expand first.
The patient count threshold exists to ensure the provider has seen enough variation — different brow shapes, different movement patterns, different responses to the same dose in different patients — to begin developing the clinical judgment that replaces reliance on a fixed protocol. It is a floor, not a destination. Providers who have treated 200 upper face patients will find advanced training more accessible than those who have treated 50, even if both technically meet the threshold.
What a Quality Advanced Course Must Include
The advanced neurotoxin training market is full of one-day courses that cover six techniques in eight hours on a mannequin. That is not advanced training — it is an introduction to a list of things you will need to actually learn later. Here is what distinguishes a course worth taking from one that produces false confidence.
Live patient practice, not demonstration only
Lower face technique is learned through repetition with feedback, not through observation. A course where you watch the trainer inject and then practice on a mannequin or a fellow student has not prepared you to treat a paying patient. The only way to develop the palpation skill, the depth calibration, and the real-time decision-making that advanced lower face injection requires is to practice on live patients under direct supervision. If a course you are evaluating does not include supervised live patient injections, it is not ready to produce competent advanced injectors — and it should tell you that in its marketing.
Anatomy taught functionally, not just visually
An advanced training course should teach anatomy in terms of what the muscle does, what happens when you weaken it, what adjacent structures are at risk at different depths, and how to palpate the relevant landmarks before injecting. Diagrams are a starting point. The clinical skill is understanding the relationship between what you feel under your fingers, what lies beneath the skin at that location, and what your injection is likely to reach at a given depth and angle. A course that teaches anatomy only through slides and diagrams has taught you to recognize a picture — not to inject a patient.
Complication management, specifically
Every advanced technique has a specific, technique-related complication profile. DAO correction has a specific wrong placement that causes depressor labii weakness. Masseter reduction has a specific superficial injection error that produces a visible bolus. The Nefertiti lift has specific depth errors that affect marginal mandibular nerve function. A quality advanced course does not mention complications generically — it teaches the specific error associated with each technique and the management protocol for each outcome, including what to tell the patient, how long to expect it to last, and what, if anything, can be done to address it earlier.
Written protocols you can actually use
You should leave an advanced training course with written treatment protocols — not marketing copy or general descriptions, but clinical documents that specify the muscle target, the injection depth, the dose range, the number of injection points, the contraindications, and the post-treatment instructions for each technique covered. These documents serve two purposes: they support your clinical decision-making in the weeks after training while technique is still being consolidated, and they form the foundation of the standing orders your medical director will need to write to authorize your expanded service menu.
The compliance conversation
An advanced training course that does not address the medical director and standing order implications of expanding your service menu has left out a material part of your education. When you add lower face neurotoxins to your practice, your existing standing orders almost certainly do not cover them — because they were written for the service menu you had when you onboarded your director. Before you treat your first masseter patient, your medical director needs to have reviewed and signed standing orders that specifically authorize that treatment, at that dose range, for that indication. A course that sends you home with new skills but no framework for updating your compliance documentation has created a liability gap you may not know exists.
Every provider who trains with Naomi leaves with written protocols, a clinical framework for each technique, and explicit guidance on the standing orders their medical director will need to update. The training is hands-on from the first hour, and Naomi is in the room for every injection. The course is designed for providers who are genuinely ready to advance — not for those looking to add a line item to their service menu without the clinical foundation to support it.
The Compliance Layer: What Changes When You Expand
Most providers who complete advanced training understand that they need to add new services to their website and update their price list. Fewer understand that they need to update their medical director documentation before they offer those services to a single patient. Here is what needs to change at the practice level when lower face neurotoxins are added.
- New standing orders for each technique. Your medical director must write and sign standing orders that specifically authorize each new application — masseter, DAO, Nefertiti, hyperhidrosis — with service-specific dosing parameters, contraindication criteria, and complication response guidelines. Generic standing orders written for upper face neuromodulators do not cover these applications.
- Updated consent documentation. Most lower face neurotoxin applications are off-label uses of FDA-approved products. Your consent forms must acknowledge the off-label status, describe the specific risks associated with each treatment, and document that the patient was informed and agreed. A consent form written for standard Botox does not accomplish this for masseter reduction or DAO correction.
- Service-specific intake screening. Masseter reduction has contraindications — neuromuscular disorders, certain medications, history of facial nerve damage — that are not covered by a standard aesthetic intake form. Hyperhidrosis treatment has its own screening considerations. Your intake process needs to capture these before the patient reaches the treatment room.
- Emergency protocol review. The complication profile for lower face injections extends to outcomes that upper face protocols do not address. Specifically, a provider offering lower face work should have a written protocol for managing facial muscle weakness of functional significance — what to tell the patient, the expected timeline, and the escalation criteria that would prompt a referral.
None of this is complicated to implement. But it needs to happen before the first patient, not after the first complaint. The practices that find themselves in regulatory difficulty are almost never those that had bad clinical outcomes — they are those that had undocumented clinical operations when the outcome occurred.